Welcome to our dedicated page for Carisma Therapeutics news (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.
Carisma Therapeutics Inc. reports developments tied to its macrophage- and monocyte-engineering therapeutics platform, including liver fibrosis, oncology, autoimmune-disease research, and CAR-M programs. Company updates have covered preclinical data, pipeline reprioritization, the discontinuation of the anti-HER2 program, collaboration-related programs with Moderna, and strategic alternatives for remaining assets.
Recent corporate-status news has also addressed workforce reductions, asset monetization efforts, Nasdaq suspension and delisting matters, OTCID trading under CARM, and SEC deregistration steps for the company’s common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 14, 2023, Carisma Therapeutics (Nasdaq: CARM) announced that three abstracts were accepted for presentation at the AACR Annual Meeting from April 14-19 in Orlando, FL. The presentations highlight Carisma's innovative cell therapy platform focused on engineered macrophages for treating difficult cancers. Key studies include a Phase 1 trial of autologous anti-HER2 CAR-M in HER2-positive solid tumors and advancements in a mesothelin-targeting CAR-M program. These findings demonstrate the potential of macrophage-based therapies to improve outcomes for patients with advanced solid tumors. Carisma aims to address immunosuppression and inflammation in cancer treatment through its unique platforms.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has appointed Mark R. Sullivan as Chief Legal Officer and Corporate Secretary, effective immediately. Sullivan brings extensive legal expertise in the life sciences sector, having previously served as General Counsel for Sesen Bio and MModal Inc. CEO Robert Barrow expressed optimism about Sullivan's contributions during a transformative phase for MindMed, which is advancing its clinical programs targeting brain health disorders. The company is focused on developing innovative treatments and improving patient outcomes. MindMed trades under the symbol MNMD on NASDAQ and MMED on the NEO Exchange.
Carisma Therapeutics Inc. (Nasdaq: CARM) announced its participation in several key healthcare and investor conferences throughout April 2023. Highlights include:
- 2023 Cell & Gene Meeting on the Med: Tom Wilton, Chief Business Officer, will present on April 13 in Barcelona, Spain.
- AACR Annual Meeting 2023: Carisma will present three data abstracts related to engineered macrophages from April 14-19 in Orlando, Florida.
- Needham 22nd Annual Virtual Healthcare Conference: Steven Kelly, CEO, will engage in a fireside chat on April 20.
- Chardan's 7th Annual Genetic Medicines & Cell Therapy Summit: On April 24, Steven Kelly and Michael Klichinsky will participate in a fireside chat.
Webcasts of these events will be available post-presentation.
Carisma Therapeutics Inc. (Nasdaq: CARM) successfully completed its merger with Sesen Bio, commencing trading under the ticker symbol 'CARM'. The merger provided a cash position of $105.3 million, anticipated to fund operations through 2024. In 2022, the company recorded collaboration revenues of $9.8 million with Moderna and reported a net loss of $61.2 million, driven by increased research and development expenses. Key milestones include additional data from its Phase 1 CT-0508 study and submission of an IND application for CT-0525, expected in the latter half of 2023. The company aims for significant advancements in solid tumor immunotherapy.